Discover the novel hormone revolutionizing our understanding of cardiac development and its therapeutic potential
Explore the ScienceImagine a microscopic architect working silently during the earliest moments of life, directing the formation of that most vital organ—the human heart. For decades, scientists knew this architect existed through its effects but couldn't identify it.
Then, in 2013, researchers discovered a remarkable hormone called ELABELA (also known as Toddler or Apela), a key player in cardiac development that acts as a new endogenous ligand for the previously mysterious APJ receptor 3 .
This discovery not only solved a longstanding puzzle in developmental biology but also opened exciting new pathways for treating heart disease, hypertension, and other conditions.
The search began for APJ's other activation key—a quest that would take researchers through years of investigation before finally culminating in an unexpected discovery.
The discrepancy between APJ and apelin knockout phenotypes suggested another ligand must exist 5 .
The breakthrough came in 2013 when two independent research teams identified a previously overlooked peptide that would be named ELABELA (ELA) 3 .
The discovery was made not through traditional protein purification but by mining genetic databases for conserved sequences that might encode secreted peptides.
Researchers made a crucial discovery when they found that zebrafish embryos lacking ELA developed severe heart defects or no heart at all—surprisingly mirroring the abnormalities seen in APJ-deficient embryos 3 .
This suggested that ELA and APJ were in the same biological pathway essential for proper heart formation.
Simultaneously, another research group identified the same peptide and named it "Toddler" for its role in promoting cell movement during gastrulation—the stage when the embryo begins to form distinct layers 3 .
The dual naming reflects the peptide's dual functions in both early cell movement and later heart development.
Though both ELA and apelin activate the same APJ receptor, they exhibit fascinating differences in their expression patterns and functions 5 8 .
During development, ELA expression begins earlier than apelin, explaining why APJ deficiency causes more severe defects than apelin deficiency 5 . ELA is present during gastrulation, while apelin expression only initiates later in development.
Studying a peptide hormone like ELABELA requires specialized tools and techniques. Here are some of the key reagents that have advanced our understanding of this fascinating hormone:
5+
Techniques
8+
Detection Methods
4+
Organisms
200+
Research Papers
The discovery of ELABELA's cardiovascular effects has ignited excitement in the medical community, particularly for treating heart disease and related conditions 4 .
Heart failure remains a leading cause of mortality worldwide. The ELA-APJ system offers several potential benefits for heart failure patients:
Animal studies show that administering ELA can improve cardiac function in models of heart failure, suggesting therapeutic potential 4 .
Pregnant women with preeclampsia show reduced ELA levels 4 .
Interestingly, ELA but not apelin knockout pregnant mice develop preeclampsia-like symptoms including proteinuria and elevated blood pressure, which can be normalized by infusion of recombinant ELA .
This suggests ELA replacement therapy might benefit preeclampsia patients.
Current research is focused on developing stable ELA analogs that could be used therapeutically for various cardiovascular conditions.